Targeting IGF1R through an antisense oligodeoxynucleotide (IMV-001) has proven to be an excellent strategy to increase the immunogenicity of cancer cells as demonstrated by the use of the IGV001 cancer vaccine (95, 96). Here, IGF1R is linked to cancer.